Javascript must be enabled to continue!
Mutant mice lacking alternatively spliced p53 isoforms unveil Ackr4 as a male-specific prognostic factor in Myc-driven B-cell lymphomas
View through CrossRef
Abstract
The
Trp53
gene encodes several isoforms of elusive biological significance. Here we show that mice lacking the
Trp53
Alternatively Spliced (AS) exon, thereby expressing the canonical p53 protein but not isoforms with the AS C-terminus, have unexpectedly lost a male-specific protection against Myc-induced B-cell lymphomas. Lymphomagenesis was delayed in p53
+/+
Eμ-Myc males compared to p53
ΔAS/ΔAS
Eμ-Myc males, but also compared to p53
+/+
Eμ-Myc and p53
ΔAS/ΔAS
Eμ-Myc females. Pre-tumoral splenic cells from p53
+/+
Eμ-Myc males exhibited a higher expression of
Ackr4,
encoding an atypical chemokine receptor with tumor suppressive effects. We identified
Ackr4
as a p53 target gene whose p53-mediated transactivation is inhibited by estrogens, and as a male-specific factor of good prognosis relevant for murine Eμ-Myc-induced and human Burkitt lymphomas. Furthermore, the knockout of
ACKR4
increased the chemokine-guided migration of Burkitt lymphoma cells. These data demonstrate the functional relevance of alternatively spliced p53 isoforms and reveal sex disparities in Myc-driven lymphomagenesis.
Title: Mutant mice lacking alternatively spliced p53 isoforms unveil
Ackr4
as a male-specific prognostic factor in Myc-driven B-cell lymphomas
Description:
Abstract
The
Trp53
gene encodes several isoforms of elusive biological significance.
Here we show that mice lacking the
Trp53
Alternatively Spliced (AS) exon, thereby expressing the canonical p53 protein but not isoforms with the AS C-terminus, have unexpectedly lost a male-specific protection against Myc-induced B-cell lymphomas.
Lymphomagenesis was delayed in p53
+/+
Eμ-Myc males compared to p53
ΔAS/ΔAS
Eμ-Myc males, but also compared to p53
+/+
Eμ-Myc and p53
ΔAS/ΔAS
Eμ-Myc females.
Pre-tumoral splenic cells from p53
+/+
Eμ-Myc males exhibited a higher expression of
Ackr4,
encoding an atypical chemokine receptor with tumor suppressive effects.
We identified
Ackr4
as a p53 target gene whose p53-mediated transactivation is inhibited by estrogens, and as a male-specific factor of good prognosis relevant for murine Eμ-Myc-induced and human Burkitt lymphomas.
Furthermore, the knockout of
ACKR4
increased the chemokine-guided migration of Burkitt lymphoma cells.
These data demonstrate the functional relevance of alternatively spliced p53 isoforms and reveal sex disparities in Myc-driven lymphomagenesis.
Related Results
Mutant mice lacking alternatively spliced p53 isoforms unveil Ackr4 as a male-specific prognostic factor in Myc-driven B-cell lymphomas
Mutant mice lacking alternatively spliced p53 isoforms unveil Ackr4 as a male-specific prognostic factor in Myc-driven B-cell lymphomas
Abstract
The gene encoding p53, a major tumor suppressor protein, encodes several alternative isoforms of elusive biological significance. Here we show that mice la...
Mutant mice lacking alternatively spliced p53 isoforms unveil Ackr4 as a male-specific prognostic factor in Myc-driven B-cell lymphomas
Mutant mice lacking alternatively spliced p53 isoforms unveil Ackr4 as a male-specific prognostic factor in Myc-driven B-cell lymphomas
Abstract
The Trp53 gene encodes several isoforms of elusive biological significance. Here we show that mice lacking the Trp53 Alternatively Spliced (AS) exon, there...
Mutant mice lacking alternatively spliced p53 isoforms unveil Ackr4 as a male-specific prognostic factor in Myc-driven B-cell lymphomas
Mutant mice lacking alternatively spliced p53 isoforms unveil Ackr4 as a male-specific prognostic factor in Myc-driven B-cell lymphomas
The
Trp53
gene encodes several isoforms of elusive biological significance. Here, we show that mice lacking the
Trp53
...
Mutant mice lacking alternatively spliced p53 isoforms unveil Ackr4 as a male-specific prognostic factor in Myc-driven B-cell lymphomas
Mutant mice lacking alternatively spliced p53 isoforms unveil Ackr4 as a male-specific prognostic factor in Myc-driven B-cell lymphomas
The
Trp53
gene encodes several isoforms of elusive biological significance. Here, we show that mice lacking the
Trp53
...
Improving immunotherapy in high-grade B-cell lymphoma
Improving immunotherapy in high-grade B-cell lymphoma
MYC is a transcription factor that upon deregulation acts as an oncogene. Cancer patients with MYC overexpression face significant worse outcomes to treatment with (immuno)chemothe...
Abstract 1176: Bypassing the dominant-negative effect of mutant p53 in cancer cells
Abstract 1176: Bypassing the dominant-negative effect of mutant p53 in cancer cells
Abstract
The tumor suppressor p53 is mutated in more than 50% of all cancers. The transcriptional activity of p53 depends on localization to the nucleus and formatio...
Abstract 422: Novel approach to destabilization of oncogenic mutant p53 and therapeutic implications
Abstract 422: Novel approach to destabilization of oncogenic mutant p53 and therapeutic implications
Abstract
Introduction: Mutant p53 drives several hallmarks of cancer through a gain-of-function oncogenic program. The oncogenicity of mutant p53 includes sustained ...
Abstract 1706: Investigating the interaction between ETS family members and mutant p53
Abstract 1706: Investigating the interaction between ETS family members and mutant p53
Abstract
Cancer cases are on the rise globally requiring a deeper understanding of the disease and identification of novel therapeutic targets. Mutations in genes of...

